Rotator Cuff TendinosisPhase 1NCT04640662
The Effects of Platelet-Rich Plasma Versus Prolotherapy On Rotator Cuff Tendinopathy: A Randomized Controlled Trial.
A Phase 1 study testing Platelet-Rich Plasma and Prolotherapy in people with Rotator Cuff Tendinosis and Supraspinatus Strain, run by University of Malaya at 1 site in Malaysia.
Trial summary
Rotator cuff tendinopathy is the common cause of shoulder pain in the working-age group and the elderly (1). The condition reported takes an average of 10 months or longer to recover. Treatment ranges from non-surgical therapy through exercise, physiotherapy, injections to surgery (2). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Rotator Cuff Tendinosis, Supraspinatus Strain, PRP
- What is being tested?
- Platelet-Rich Plasma and Prolotherapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteMalaysia
- Study dates
- 17 Feb 2020to 25 Sep 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Chronic shoulder pain more than 3 months
- Diagnosis of supraspinatus tendinopathy by Sports Physician or Orthopaedic
- Diagnosis by ultrasound or MRI
Who cannot join
- Patients with the following medical condition: autoimmune rheumatology disease, blood disorder
- Patients with the following shoulder conditions: referred pain from cervical, recent shoulder surgery, shoulder instability, complete rotator cuff tear, adhesive capsulitis
- Patients with the following medications: anti-coagulant treatment, steroid injection in less than 6 months
Trial locations and contacts
1 site in 1 country.
Malaysia1 site
University of Malaya Medical Centre
Petaling Jaya, Kuala Lumpur, 59100
About this study
Official title: The Effects of Platelet Rich Plasma Versus Prolotherapy on Pain and Function in Rotator Cuff Tendinopathy: A Randomized Clinical Trial
Rotator cuff tendinopathy is the common cause of shoulder pain in the working-age group and the elderly (1). The condition reported takes an average of 10 months or longer to recover. Treatment ranges from non-surgical therapy through exercise, physiotherapy, injections to surgery (2). Injection of steroid was used in many cases to reduce pain. However, steroid only provided short term pain relief and did not resolve the main pathology. Emerging of biologics agents such as platelet-rich plasma (PRP) and prolotherapy are alternative to the treatment (3). PRP is a concentrated platelet which contains a high concentration of protein that helps in the healing process (4). Prolotherapy with the commonly used substance dextrose works by attracting inflammatory substrate and stimulate own body healing process (5).
This study takes place at the University of Malaya Medical Centre. Participants diagnosed with rotator cuff tendinopathy are randomly divided into two groups- Platelet Rich Plasma (PRP) group and Prolotherapy group. All participants are screened by the researcher for the eligibility to join the study. Subsequently, the participants undergo baseline assessment on the clinical, functional, biomechanics and ultrasound. Blood is taken in all patient, to make the patient blind to the intervention they received. In the PRP group- the participants received 2ml of PRP, and in prolotherapy group, the participants received 2ml of 16.5% dextrose solution. A single injection is done by an experienced Sports Physician using ultrasound-guided into the injured area. The assessor at baseline, and follow up are blinded to the intervention. The participants need to come for follow up at 3 weeks, 6 weeks, 3 months and 6 months after injection.
Systematic reviews showed the benefit of biologics agent to treat tendon injuries, especially for lateral epicondylitis and patellar tendinitis (6). Many studies for soft tissue injury were on PRP compared to prolotherapy. This study hypothesized that both treatments result in significant improvement in pain and function after the intervention. PRP might provide more significant improvement compared to prolotherapy.
Read the detailed description
Study design This study is a randomized, double-blind, controlled trial conducted at the University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
Patients The patients will be recruited from the following clinics: Sports Medicine, orthopaedic, rheumatology, outpatient and staff health. Notice of study invitation in this study will be distributed to all the respective clinic. Patients with a confirm diagnosis of supraspinatus tendinopathy by ultrasound or MRI will be invited to participate in this study. Study screening will be carried out to ensure the inclusion and exclusion criteria are fulfilled by the research team in Sports Medicine Clinic.
Procedures
PRP group Patients under PRP group will receive a single 2 mL injection of PRP into the injury site under ultrasound guidance administered by a sports physician. The PRP will be prepared using a commercial kit, Y-Cell BioKit Systems.
Prolotherapy group Patients in the prolotherapy group will receive a single 2 mL injection of 16.5% dextrose solution administered under ultrasound guidance.
Injection technique Injection will be performed in the Sports Medicine Clinic using aseptic technique. Both the PRP and prolotherapy will be prepared in a syringe and covered with a black tape to ensure the patients did not know the content of the syringe. Patients will be placed in the supine position and will be requested not to turn their head during the procedure. A 22 G needle will be used for injection under ultrasound guided.
Following injection, cryotherapy will be applied for 15 min. Upon discharge, patients will be advised to rest the injected shoulder for the next 48 hours and to avoid taking NSAIDs.
Rehabilitation program Patients will receive a booklet for shoulder stretching and strengthening exercise. A logbook will be provided for the patients to record their exercise session. Rehabilitation sessions will be advise to commenced only day three of injection.
Sample size The sample size was estimated based on the primary outcome of functional score. Improvement was defined by a decrease in the mean Shoulder Pain and Disability Index (SPADI) of 17.7 ± 3.7 in the platelet-rich plasma group11 and 16.12 ± 12.8211 for prolotherapy. For this study, the sample size was calculated after taking into account the desired statistical significance level set at 5%, and the power of the study set at 80%, with type I error rate of less than 0.05 is permitted and a false-negative rate of less than 0.20. The sample size is calculated using the G*Power version 3.1.9.2 software11. With the assumption of 30% drop out, hence, to detect a difference in the functional outcome, a minimum of 30 patients in each group is required.
Randomization Randomization will be performed using computer-generated block randomization of ten. Subjects will be randomized into either PRP group or Prolo group.
Blinding The patients and assessors will be blind to the intervention. Two sports physician who not directly involved in the randomization and injection will perform the outcome measure assessment.
Outcomes
Patients characteristics Patients sociodemographic information, including gender, date of birth, ethnic background, job description and recreational activities will be recorded. Information related to the shoulder pain such as duration and other past rehabilitation and treatment will also be documented.
Primary outcome measures The primary outcome of this study is pain score using the visual analog score (VAS) score and shoulder function using shoulder pain and disability index (SPADI) score.
VAS score (7) is a continuous scale, 10 cm length with the left most anchor indicate "no pain" (0) to "extreme pain" (10).
SPADI was used to measure shoulder pain and disability in an outpatient setting within the recent 1 week. It contains 13 items that assess pain and disability. SPADI reveals good construct validity, correlating well with other specific shoulder questionnaires and responsive to change over time (8).
Secondary outcome measures
- Constant-Murley score assessed four aspects of shoulder injury which consist of two subjective item- pain and activities of daily living (ADL) and two objective item- range of motion (ROM) and strength. This score was used in many shoulder studies and had good response to change quality (9).
- Clinical test which consist of special test
- Biomedical test which consist of shoulder ROM using goniometer, strength using dynamometer and periscapular muscle activities using electromyogram.
- Adverse effect of the injections will also be recorded.
Data collection and management Data will be collected from patients at baseline, 3 weeks, 6 weeks, 3 months and 6 months. All data collected will be stored securely in a locked cabinet in Sports Medicine Department throughout the trial and only can be access by the researcher involved. To ensure confidentiality, each patient will have the trial identification number.
Statistical analysis The outcome variables will be analyzed with the principle of intention-to-treat (ITT). The mean VAS score and SPADI between groups will be compared using either the parametric independent t-test or non-parametric test using Mann-Whitney U test. The secondary outcome measures will be examine using linear mixed- model analysis. All statistical analysis will be performed using the SPSS V.25.0 (SPSS), and a p value of <0.05 will be considered to be significant.
Ethics and dissemination The study was approved by the Medical Research Ethics Committee of the University of Malaya Medical Centre (MREC ID: 201977-7623). This trial was registered at the National Medical Research Register (NMRR-19-1658-48279). Participation in this study is strictly voluntary. Possible patients will be informed of all the procedures involved in the reserach verbally and by the patient's information sheets. Patients will be required to sign the informed consent form before participation. Patient will be allowed to withdraw from the study at any time. Results from this study will be presented at scientific conferences and publish in journal.
- Conditions
- Rotator Cuff Tendinosis, Supraspinatus Strain, PRP
- Being tested
- Platelet-Rich Plasma, Prolotherapy
- Keywords
- Platelet-rich plasma, Prolotherapy, Biologics, Tendinopathy
- Medical subject headings
- Rotator Cuff Injuries, Tendinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Platelet-Rich PlasmaBiological
Also called PRP
Single-injection of 2 ml PRP into the lesion under ultrasound-guided
ProlotherapyBiological
Also called Prolo
Single-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided
| Study group | Role | What they receive |
|---|---|---|
| Platelet-Rich plasma | Experimental | 2 ml PRP using commercial kit- YCell Biokit Receives: Biological: Platelet-Rich Plasma; Biological: Prolotherapy |
| Prolotherapy | Active comparator | 2 ml 16.5% Dextrose solution Receives: Biological: Platelet-Rich Plasma; Biological: Prolotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain Reduction change from baseline
Visual analog score (VAS) score will be used. The scale is between 0 to 10; 0 is no pain, 10 is the worst pain imaginable
Measured: 3 weeks, 6 weeks, 3 months and 6 months
Functional score change from baseline
Shoulder Pain and Disability Index (SPADI) questionnaire Two subscales namely pain and disability. Pain scale is from 0 to 10; 0 is no pain, 10 is the worst pain imaginable
Disability scale range from 0 to 10; 0 no difficulty, 10 is so difficult it requires help
Measured: 3 weeks, 6 weeks, 3 months and 6 months
Secondary outcomes (4)
Strength in kg
The test will use Commander Dynamometer. The changes in strength (kg) from baseline will be assessed during each follow up
Measured: 3 weeks, 6 weeks, 3 months and 6 months
Range of Movement
Goniometer will be used for the assessment. The changes in the range of motion in degrees from baseline will be assessed at all follow up
Measured: 3 weeks, 6 weeks, 3 months and 6 months
Peri-scapular Muscle activity
Electromyogram will be used for the assessment. Muscle amplitude will be recorded at baseline and at follow up
Measured: 6 weeks, 3 months and 6 months
Ultrasound findings The parameters will be on tendon thickness, neo-vascularaization and tear size
The ultrasound of the supraspinatus will be assessed to look for changes in the tendinopathy characteristics at baseline and follow up
Measured: 6 weeks, 3 months and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2020
- Study start17 Feb 2020
- Primary completion30 Jun 2021
- Study completion25 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Rotator Cuff TendinosisStudies of the same condition, open and under way.
- More trials run by University of MalayaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Malaya
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Samihah Abdul Karim, University of Malaya
- Investigators
- Samihah A. Karim, MD, Principal investigator, University of Malaya
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04640662
- Sponsor's protocol ID
- PV062-2018
- Status last verified
- Oct 2022
- First submitted
- 11 Nov 2020
- Last updated
- 2 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD sharing for the following: * Study Protocol * Clinical Study Report (CSR)
Publications
Lin MT, Chiang CF, Wu CH, Huang YT, Tu YK, Wang TG. Comparative Effectiveness of Injection Therapies in Rotator Cuff Tendinopathy: A Systematic Review, Pairwise and Network Meta-analysis of Randomized Controlled Trials. Arch Phys Med Rehabil. 2019 Feb;100(2):336-349.e15. doi: 10.1016/j.apmr.2018.06.028. Epub 2018 Aug 2.
PubMed 300768011. Littlewood, C., S. May, and S. Walters, Epidemiology of Rotator Cuff Tendinopathy: A Systematic Review. Shoulder & Elbow, 2013. 5(4): p. 256-265.
Lewis J, McCreesh K, Roy JS, Ginn K. Rotator Cuff Tendinopathy: Navigating the Diagnosis-Management Conundrum. J Orthop Sports Phys Ther. 2015 Nov;45(11):923-37. doi: 10.2519/jospt.2015.5941. Epub 2015 Sep 21.
PubMed 26390274Hurley ET, Hannon CP, Pauzenberger L, Fat DL, Moran CJ, Mullett H. Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials. Arthroscopy. 2019 May;35(5):1584-1591. doi: 10.1016/j.arthro.2018.10.115. Epub 2019 Apr 15.
PubMed 31000394Trebinjac S and Kitchbi. Long-term effect of Prolotherapy on symptomatic rotator cuff tendinopathy. Journal of Health Sciences 2015;5(3):93-98
Docheva D, Muller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev. 2015 Apr;84:222-39. doi: 10.1016/j.addr.2014.11.015. Epub 2014 Nov 21.
PubMed 25446135
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Platelet Rich Plasma Versus Prolotherapy on Pain and Function in Rotator Cuff Tendinopathy: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT04640662
- Acronym / sponsor ID
- PV062-2018
- Conditions
- Rotator Cuff Tendinosis, Supraspinatus Strain, PRP
- Keywords
- Platelet-rich plasma, Prolotherapy, Biologics, Tendinopathy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- University of MalayaUniversity, hospital or other
- Study start
- 17 Feb 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 25 Sep 2021 (actual)
- First posted
- 23 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rotator cuff tendinopathy is the common cause of shoulder pain in the working-age group and the elderly (1). The condition reported takes an average of 10 months or longer to recover. Treatment ranges from non-surgical therapy through exercise, physiotherapy, injections to surgery (2). Injection of steroid was used in many cases to reduce pain. However, steroid only provided short term pain relief and did not resolve the main pathology. Emerging of biologics agents such as platelet-rich plasma (PRP) and prolotherapy are alternative to the treatment (3). PRP is a concentrated platelet which contains a high concentration of protein that helps in the healing process (4). Prolotherapy with the commonly used substance dextrose works by attracting inflammatory substrate and stimulate own body healing process (5).
This study takes place at the University of Malaya Medical Centre. Participants diagnosed with rotator cuff tendinopathy are randomly divided into two groups- Platelet Rich Plasma (PRP) group and Prolotherapy group. All participants are screened by the researcher for the eligibility to join the study. Subsequently, the participants undergo baseline assessment on the clinical, functional, biomechanics and ultrasound. Blood is taken in all patient, to make the patient blind to the intervention they received. In the PRP group- the participants received 2ml of PRP, and in prolotherapy group, the participants received 2ml of 16.5% dextrose solution. A single injection is done by an experienced Sports Physician using ultrasound-guided into the injured area. The assessor at baseline, and follow up are blinded to the intervention. The participants need to come for follow up at 3 weeks, 6 weeks, 3 months and 6 months after injection.
Systematic reviews showed the benefit of biologics agent to treat tendon injuries, especially for lateral epicondylitis and patellar tendinitis (6). Many studies for soft tissue injury were on PRP compared to prolotherapy. This study hypothesized that both treatments result in significant improvement in pain and function after the intervention. PRP might provide more significant improvement compared to prolotherapy.
Detailed description
Study design This study is a randomized, double-blind, controlled trial conducted at the University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
Patients The patients will be recruited from the following clinics: Sports Medicine, orthopaedic, rheumatology, outpatient and staff health. Notice of study invitation in this study will be distributed to all the respective clinic. Patients with a confirm diagnosis of supraspinatus tendinopathy by ultrasound or MRI will be invited to participate in this study. Study screening will be carried out to ensure the inclusion and exclusion criteria are fulfilled by the research team in Sports Medicine Clinic.
Procedures
PRP group Patients under PRP group will receive a single 2 mL injection of PRP into the injury site under ultrasound guidance administered by a sports physician. The PRP will be prepared using a commercial kit, Y-Cell BioKit Systems.
Prolotherapy group Patients in the prolotherapy group will receive a single 2 mL injection of 16.5% dextrose solution administered under ultrasound guidance.
Injection technique Injection will be performed in the Sports Medicine Clinic using aseptic technique. Both the PRP and prolotherapy will be prepared in a syringe and covered with a black tape to ensure the patients did not know the content of the syringe. Patients will be placed in the supine position and will be requested not to turn their head during the procedure. A 22 G needle will be used for injection under ultrasound guided.
Following injection, cryotherapy will be applied for 15 min. Upon discharge, patients will be advised to rest the injected shoulder for the next 48 hours and to avoid taking NSAIDs.
Rehabilitation program Patients will receive a booklet for shoulder stretching and strengthening exercise. A logbook will be provided for the patients to record their exercise session. Rehabilitation sessions will be advise to commenced only day three of injection.
Sample size The sample size was estimated based on the primary outcome of functional score. Improvement was defined by a decrease in the mean Shoulder Pain and Disability Index (SPADI) of 17.7 ± 3.7 in the platelet-rich plasma group11 and 16.12 ± 12.8211 for prolotherapy. For this study, the sample size was calculated after taking into account the desired statistical significance level set at 5%, and the power of the study set at 80%, with type I error rate of less than 0.05 is permitted and a false-negative rate of less than 0.20. The sample size is calculated using the G*Power version 3.1.9.2 software11. With the assumption of 30% drop out, hence, to detect a difference in the functional outcome, a minimum of 30 patients in each group is required.
Randomization Randomization will be performed using computer-generated block randomization of ten. Subjects will be randomized into either PRP group or Prolo group.
Blinding The patients and assessors will be blind to the intervention. Two sports physician who not directly involved in the randomization and injection will perform the outcome measure assessment.
Outcomes
Patients characteristics Patients sociodemographic information, including gender, date of birth, ethnic background, job description and recreational activities will be recorded. Information related to the shoulder pain such as duration and other past rehabilitation and treatment will also be documented.
Primary outcome measures The primary outcome of this study is pain score using the visual analog score (VAS) score and shoulder function using shoulder pain and disability index (SPADI) score.
VAS score (7) is a continuous scale, 10 cm length with the left most anchor indicate "no pain" (0) to "extreme pain" (10).
SPADI was used to measure shoulder pain and disability in an outpatient setting within the recent 1 week. It contains 13 items that assess pain and disability. SPADI reveals good construct validity, correlating well with other specific shoulder questionnaires and responsive to change over time (8).
Secondary outcome measures
- Constant-Murley score assessed four aspects of shoulder injury which consist of two subjective item- pain and activities of daily living (ADL) and two objective item- range of motion (ROM) and strength. This score was used in many shoulder studies and had good response to change quality (9).
- Clinical test which consist of special test
- Biomedical test which consist of shoulder ROM using goniometer, strength using dynamometer and periscapular muscle activities using electromyogram.
- Adverse effect of the injections will also be recorded.
Data collection and management Data will be collected from patients at baseline, 3 weeks, 6 weeks, 3 months and 6 months. All data collected will be stored securely in a locked cabinet in Sports Medicine Department throughout the trial and only can be access by the researcher involved. To ensure confidentiality, each patient will have the trial identification number.
Statistical analysis The outcome variables will be analyzed with the principle of intention-to-treat (ITT). The mean VAS score and SPADI between groups will be compared using either the parametric independent t-test or non-parametric test using Mann-Whitney U test. The secondary outcome measures will be examine using linear mixed- model analysis. All statistical analysis will be performed using the SPSS V.25.0 (SPSS), and a p value of <0.05 will be considered to be significant.
Ethics and dissemination The study was approved by the Medical Research Ethics Committee of the University of Malaya Medical Centre (MREC ID: 201977-7623). This trial was registered at the National Medical Research Register (NMRR-19-1658-48279). Participation in this study is strictly voluntary. Possible patients will be informed of all the procedures involved in the reserach verbally and by the patient's information sheets. Patients will be required to sign the informed consent form before participation. Patient will be allowed to withdraw from the study at any time. Results from this study will be presented at scientific conferences and publish in journal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Platelet-Rich plasma | Experimental | Biological: Platelet-Rich Plasma, Biological: Prolotherapy2 ml PRP using commercial kit- YCell Biokit |
| Prolotherapy | Active comparator | Biological: Platelet-Rich Plasma, Biological: Prolotherapy2 ml 16.5% Dextrose solution |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Chronic shoulder pain more than 3 months
- Diagnosis of supraspinatus tendinopathy by Sports Physician or Orthopaedic
- Diagnosis by ultrasound or MRI
Key exclusion criteria (3 listed)
- Patients with the following medical condition: autoimmune rheumatology disease, blood disorder
- Patients with the following shoulder conditions: referred pain from cervical, recent shoulder surgery, shoulder instability, complete rotator cuff tear, adhesive capsulitis
- Patients with the following medications: anti-coagulant treatment, steroid injection in less than 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Platelet-Rich PlasmaAlso: PRPSingle-injection of 2 ml PRP into the lesion under ultrasound-guided | Biological | Platelet-Rich plasma, Prolotherapy |
| ProlotherapyAlso: ProloSingle-injection of 2ml dextrose 16.5% into the lesion under ultrasound-guided | Biological | Platelet-Rich plasma, Prolotherapy |
Primary outcome
Pain Reduction change from baseline
Time frame: 3 weeks, 6 weeks, 3 months and 6 months
Visual analog score (VAS) score will be used. The scale is between 0 to 10; 0 is no pain, 10 is the worst pain imaginable
Functional score change from baseline
Time frame: 3 weeks, 6 weeks, 3 months and 6 months
Shoulder Pain and Disability Index (SPADI) questionnaire Two subscales namely pain and disability. Pain scale is from 0 to 10; 0 is no pain, 10 is the worst pain imaginable Disability scale range from 0 to 10; 0 no difficulty, 10 is so difficult it requires help
4 secondary outcomes
Strength in kg
Time frame: 3 weeks, 6 weeks, 3 months and 6 months
Range of Movement
Time frame: 3 weeks, 6 weeks, 3 months and 6 months
Peri-scapular Muscle activity
Time frame: 6 weeks, 3 months and 6 months
Ultrasound findings The parameters will be on tendon thickness, neo-vascularaization and tear size
Time frame: 6 weeks, 3 months and 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2022.
- Background: PubMed 30076801Lin MT, Chiang CF, Wu CH, Huang YT, Tu YK, Wang TG. Comparative Effectiveness of Injection Therapies in Rotator Cuff Tendinopathy: A Systematic Review, Pairwise and Network Meta-analysis of Randomized Controlled Trials. Arch Phys Med Rehabil. 2019 Feb;100(2):336-349.e15. doi: 10.1016/j.apmr.2018.06.028. Epub 2018 Aug 2.
- Results publication1. Littlewood, C., S. May, and S. Walters, Epidemiology of Rotator Cuff Tendinopathy: A Systematic Review. Shoulder & Elbow, 2013. 5(4): p. 256-265.
- Results publication: PubMed 26390274Lewis J, McCreesh K, Roy JS, Ginn K. Rotator Cuff Tendinopathy: Navigating the Diagnosis-Management Conundrum. J Orthop Sports Phys Ther. 2015 Nov;45(11):923-37. doi: 10.2519/jospt.2015.5941. Epub 2015 Sep 21.
- Results publication: PubMed 31000394Hurley ET, Hannon CP, Pauzenberger L, Fat DL, Moran CJ, Mullett H. Nonoperative Treatment of Rotator Cuff Disease With Platelet-Rich Plasma: A Systematic Review of Randomized Controlled Trials. Arthroscopy. 2019 May;35(5):1584-1591. doi: 10.1016/j.arthro.2018.10.115. Epub 2019 Apr 15.
- Results publicationTrebinjac S and Kitchbi. Long-term effect of Prolotherapy on symptomatic rotator cuff tendinopathy. Journal of Health Sciences 2015;5(3):93-98
- Results publication: PubMed 25446135Docheva D, Muller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev. 2015 Apr;84:222-39. doi: 10.1016/j.addr.2014.11.015. Epub 2014 Nov 21.
- Individual participant dataSharing planned: Yes. IPD sharing for the following: * Study Protocol * Clinical Study Report (CSR)
Related trials for Rotator Cuff Tendinosis
Recruiting
Effects of Rotator Cuff Drills Versus Progressive Resistance Exercises on Chronic Rotator Cuff Tendinopathy
Rotator Cuff Tendinosis
Recruiting
Embolization Treatment of Chronic Refractory Shoulder Tendinopathy
Shoulder Pain, Tendinopathy
Recruiting
Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome - Outcomes and Mechanisms
Rotator Cuff Tendinosis, Rotator Cuff Tendinitis
Active, not recruitingPhase 4
Connective Tissue Matrix for Rotator Cuff Tendinopathy
Tendinopathy, Shoulder Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samihah A. Karim, MD principal investigator
University of Malaya
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Platelet-Rich Plasma and Prolotherapy in people with Rotator Cuff Tendinosis and Supraspinatus Strain, run by University of Malaya at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain Reduction change from baseline (time frame: 3 weeks, 6 weeks, 3 months and 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04640662, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.